PCa Commentary | Volume 157 – September 2021
This Commentary considers the increased incidence of and evolving treatment options for metastatic hormone-sensitive prostate cancer.
Read MoreSelect Page
Edward Weber, MD, is a retired medical oncologist living in Seattle, Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, Dr. Weber attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington.
A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then pursued a fellowship in hematology and oncology at the University of Washington.
His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.
Toward the end of his career, he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002, he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.
Posted by Edward Weber, MD | Sep 2021
This Commentary considers the increased incidence of and evolving treatment options for metastatic hormone-sensitive prostate cancer.
Read MorePosted by Edward Weber, MD | Aug 2021
This Commentary looks at Pylarify, a new PET/CT imaging agent for staging primary prostate cancer and recurrence.
Read MorePosted by Edward Weber, MD | Jul 2021
This Commentary looks at causes and management options for hot flashes, a common side effect of ADT treatment for prostate cancer.
Read MorePosted by Edward Weber, MD | Jun 2021
This Commentary looks at the current state of causes, diagnosis and treatment for neuroendocrine prostate cancer.
Read MorePosted by Edward Weber, MD | May 2021
This Commentary provides an overview of PSMA-targeted radioligand therapy with Lutetium-177 or Actinium-225 and positive impact on progression-free survival.
Read More